X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA AUROBINDO PHARMA AJANTA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 20.7 19.6 105.5% View Chart
P/BV x 4.8 3.7 130.5% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 AJANTA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
AUROBINDO PHARMA
Mar-18
AJANTA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,818809 224.7%   
Low Rs1,106504 219.4%   
Sales per share (Unadj.) Rs239.5281.1 85.2%  
Earnings per share (Unadj.) Rs52.841.4 127.7%  
Cash flow per share (Unadj.) Rs59.550.9 117.0%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs230.0199.4 115.3%  
Shares outstanding (eoy) m88.77585.88 15.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.12.3 261.4%   
Avg P/E ratio x27.715.9 174.4%  
P/CF ratio (eoy) x24.612.9 190.4%  
Price / Book Value ratio x6.43.3 193.1%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m129,782384,630 33.7%   
No. of employees `0006.817.3 39.2%   
Total wages/salary Rs m3,76521,308 17.7%   
Avg. sales/employee Rs Th3,128.49,500.7 32.9%   
Avg. wages/employee Rs Th554.01,229.4 45.1%   
Avg. net profit/employee Rs Th689.71,397.9 49.3%   
INCOME DATA
Net Sales Rs m21,258164,666 12.9%  
Other income Rs m2421,020 23.7%   
Total revenues Rs m21,499165,686 13.0%   
Gross profit Rs m6,58437,718 17.5%  
Depreciation Rs m5965,580 10.7%   
Interest Rs m4777 0.5%   
Profit before tax Rs m6,22632,380 19.2%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5398,183 18.8%   
Profit after tax Rs m4,68624,229 19.3%  
Gross profit margin %31.022.9 135.2%  
Effective tax rate %24.725.3 97.8%   
Net profit margin %22.014.7 149.8%  
BALANCE SHEET DATA
Current assets Rs m12,236121,878 10.0%   
Current liabilities Rs m3,46186,806 4.0%   
Net working cap to sales %41.321.3 193.8%  
Current ratio x3.51.4 251.8%  
Inventory Days Days60130 46.4%  
Debtors Days Days8468 123.6%  
Net fixed assets Rs m11,14081,037 13.7%   
Share capital Rs m177586 30.2%   
"Free" reserves Rs m20,237116,218 17.4%   
Net worth Rs m20,414116,804 17.5%   
Long term debt Rs m104,512 0.2%   
Total assets Rs m24,486211,052 11.6%  
Interest coverage x1,519.442.7 3,561.4%   
Debt to equity ratio x00 1.3%  
Sales to assets ratio x0.90.8 111.3%   
Return on assets %19.211.8 161.7%  
Return on equity %23.020.7 110.7%  
Return on capital %30.527.4 111.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66780,727 14.5%   
Fx outflow Rs m1,61634,700 4.7%   
Net fx Rs m10,05246,027 21.8%   
CASH FLOW
From Operations Rs m2,85419,548 14.6%  
From Investments Rs m-2,604-19,570 13.3%  
From Financial Activity Rs m-28,642 -0.0%  
Net Cashflow Rs m2488,922 2.8%  

Share Holding

Indian Promoters % 73.8 54.1 136.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 8.0 19.5%  
FIIs % 7.6 27.7 27.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.2 166.7%  
Shareholders   20,968 69,601 30.1%  
Pledged promoter(s) holding % 4.4 8.6 51.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  BIOCON LTD  UNICHEM LAB  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Lower; Infosys & Yes Bank Top Losers(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading mixed with stocks in the capital goods sector and metal sector.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Dec 18, 2018 03:35 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS